NEU ASX News

13 November 2024

Neuren announces A$50m on-market share buy-back program

Neuren Pharmaceuticals reveals a A$50 million share buy-back initiative.

Neuren Pharmaceuticals Share Buy-Back Stock Market News Pharmaceutical Industry

Posted on: 13/11/2024

9 August 2024

Phase 2 trial shows significant improvements in Angelman

Neuren Pharmaceuticals reports significant improvements in Angelman syndrome treatment with NNZ-2591.

Neuren Pharmaceuticals Angelman Syndrome NNZ-2591 Clinical Trial Results Stock Market News

Posted on: 09/08/2024